U.S. markets closed
  • S&P Futures

    4,165.50
    -10.75 (-0.26%)
     
  • Dow Futures

    33,991.00
    -90.00 (-0.26%)
     
  • Nasdaq Futures

    13,998.75
    -30.75 (-0.22%)
     
  • Russell 2000 Futures

    2,249.60
    -9.40 (-0.42%)
     
  • Crude Oil

    62.87
    -0.26 (-0.41%)
     
  • Gold

    1,781.30
    +1.10 (+0.06%)
     
  • Silver

    26.10
    0.00 (0.00%)
     
  • EUR/USD

    1.1973
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3819
    -0.0020 (-0.15%)
     
  • USD/JPY

    108.7580
    -0.0250 (-0.02%)
     
  • BTC-USD

    56,547.83
    -4,258.68 (-7.00%)
     
  • CMC Crypto 200

    1,277.23
    -114.48 (-8.23%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,564.84
    -118.53 (-0.40%)
     

Sanofi and Regeneron report positive skin disease trial

PARIS, June 6 (Reuters) - French drugmaker Sanofi SA and U.S. partner Regeneron Pharmaceuticals Inc said a one-year, late-stage study of dupilumab, a monoclonal antibody designed for the treatment of skin diseases, had met its main goals.

"These are the first long-term Phase 3 data that demonstrated dupilumab with topical corticosteroids was superior to topical corticosteroids alone, and provided sustained efficacy, significantly improving measures of overall disease severity, skin clearing, itching, and quality of life through one year of treatment," Regeneron Chief Scientific Officer George D. Yancopoulos said in a statement.

Sanofi said in the statement that the partners planned their first submission for regulatory approval for the treatment in the United States in the third quarter of this year.

(Reporting by James Regan; Editing by Sherry Jacob-Phillips)